International Journal of Physical Medicine & Rehabilitation
Open Access
ISSN: 2329-9096
+44 1300 500008
ISSN: 2329-9096
+44 1300 500008
Byron K Black
Posters-Accepted Abstracts: Int J Phys Med Rehabil
Type 2 diabetes is a metabolic condition in which the person??s fasting blood sugar becomes higher than normal. In 2012, diabetes affected ~29.1 million adults in the US. Its economic burden was $245 billion; this represents a 41% cost increase from 2007 to 2012. Attention is now being given to a high risk group called ??pre-diabetics? in which a person has a blood sugar that is higher than normal but does not meet the criteria for T2DM (Type 2 Diabetes Mellitus). In 2012, the estimated number of adults with pre-diabetes was 86 million and 70% of these patients transition to T2DM within 3 to 6 years. Current treatment for pre and diabetes includes pharmaceutical and lifestyle intervention. In 1995, Metformin became the medication of choice for diabetes and it is recommended by the American Diabetes Association as the first line medication. However, since 1995 the incidence of diabetes has risen almost 73% from 8 million to 29.1 million. In a study by the Diabetes Prevention Program, participants were divided into placebo, metformin or lifestyle intervention groups and followed for an average of three years. The incidence of diabetes was lower in the lifestyle group than metformin group; 58% and 31% respectively. After 10 years, the incidence of diabetes was still better in the lifestyle group than metformin group; 34% to 18% respectively. If the rise in diabetes is to be turned back then lifestyle interventions must become the first line agent.